SEER Looks 5.8% Undervalued on GF Value™

Seer Inc (SEER) shareholders Bradley Radoff and Michael Torok, owning 7.7% of shares, called for board member Meeta Gulyani's resignation, citing her lack of experience and governance engagement. The company's market cap fell over 90% since her appointment. Seer's P/S ratio is 7.92, below its historical median of 9.34, and its GF Score™ is 54/100, indicating mixed fundamentals. Insiders sold shares, while institutional ownership remains stable.

Original reporting
Published Sep 4, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 2:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SEER
Neutral
medium confidence
Mentioned
$SEER
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SEERNeutralLow
01

Why it matters

Activist letter introduces governance risk but no immediate financial transaction; potential for short-term volatility.

02

Market read

Governance activism may trigger modest price movement; broader market impact is minimal.

03

What to watch

Insider selling and weak profitability already signal downside; governance issue adds marginal risk.

Relevance 4/10Novelty 4/10Timing: September 04, 2026 (same-day activist letter)

Background

SEER is a biotech firm developing proteomic analysis tools, currently loss-making with negative cash flow and a market cap of ~$107 million.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Shareholders Bradley Radoff and Michael Torok (7.7% stake) publicly demanded board member Meeta Gulyani resign, highlighting governance concerns amid a 90% market cap decline.

Expected impact

Modest downside risk if resignation is not achieved; possible short-term rally if board responds positively.

Evidence & confidence

Activist pressure on a small-cap biotech often leads to heightened scrutiny and short-term price moves, but no concrete transaction or financial impact is disclosed.

Market effects

Governance concerns may prompt investors to reassess risk in small-cap biotech sector.

Limited to U.S. listed biotech investors.

Low; primarily affects SEER shareholders.

Counterpoint

Board resignation demand may be overblown; company could benefit from stability if Gulyani remains.

Key entities

  • Seer Inc

    NASDAQ‑listed biotech developing proteomic tools.

  • Meeta Gulyani

    Target of resignation demand.

  • Bradley Radoff

    7.7% owner calling for board change.

  • Michael Torok

    Co‑owner of 7.7% stake.

Related articles

$SEERMed

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

$SEERMed

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.